SDGR Schrodinger, Inc. NASDAQ · United States

Schrodinger (SDGR) news

Schrodinger, Inc. is a public biotech or pharmaceutical company listed on NASDAQ under the ticker SDGR, recorded under United States. aibio.space tracks 2,820 public biotech companies worldwide and publishes investor news on them.

Latest Schrodinger news

We have not published a story on Schrodinger yet. When there is news, it will appear here.

Schrodinger annual financials

Line	FY2025	FY2024
Revenue	$255.9 million	$207.5 million
Research and development	$173.1 million	$201.8 million
Net income (loss)	-$103.3 million	-$187.1 million
Cash from operations	$13.9 million	-$157.4 million
Cash and equivalents	$230.5 million	$147.3 million
Short-term investments	$164.9 million	$204.8 million

Latest balance sheet, Jun 30, 2026 (10-Q): cash and equivalents $287.9 million, plus short-term investments of $125.9 million, $413.7 million in all.

Figures as reported to the SEC in XBRL; each one links to its filing. Not adjusted, not investment advice.

Questions about Schrodinger

What is the ticker symbol of Schrodinger?

Schrodinger, Inc. trades under the ticker SDGR on NASDAQ.

Where is Schrodinger listed?

Schrodinger, Inc. is listed on NASDAQ.

Which country or territory is Schrodinger listed under?

Our directory records Schrodinger, Inc. under United States.

Does aibio.space cover Schrodinger?

aibio.space lists Schrodinger, Inc. among 2,820 public biotech companies and publishes its news here as stories appear.

What was Schrodinger's revenue last year?

$255.9 million for the fiscal year ended Dec 31, 2025, as reported to the SEC.

Is Schrodinger profitable?

Schrodinger, Inc. reported a net loss of $103.3 million for the fiscal year ended Dec 31, 2025, and generated $13.9 million of cash from operations, per its annual report to the SEC.

How much does Schrodinger spend on research and development?

$173.1 million in the fiscal year ended Dec 31, 2025, per its annual report.

How much cash does Schrodinger have?

$413.7 million in cash and short-term investments at Jun 30, 2026, per its 10-Q.

Investor discussion: Schrodinger

Members talk about Schrodinger (SDGR). Reader posts, not aibio.space reporting, and not investment advice.

Rules

Securities violations are strictly forbidden. No market manipulation, no pump-and-dump, no false or misleading statements, and no inside information.
Say whether you hold the stock. Every post states long, short or no position.
No paid or sponsored posts. Do not post for anyone who pays or rewards you.
No buy or sell calls and no price targets.
No accusations of crime or fraud against named people unless you link a court filing or a regulator's release that makes them.
No personal details and no spam. No links at all for your first 7 days as a member.

Posts that break the rules may be deleted without notice, and the account restricted or closed. See the terms and the privacy policy.

Stock chart

Price chart and quote supplied by TradingView, delayed as the exchange requires. It loads only if you choose to show it. Information only, not investment advice. Open NASDAQ:SDGR on TradingView.

Listing details

Company: Schrodinger, Inc.
Ticker: SDGR
Listing: NASDAQ
Country or territory: United States

Listing facts come from our company directory, researched on October 22, 2026. A listing record does not certify that a security currently trades. Tell us about a change. Work at this company? Claim this page.

Published and maintained by aibio.space. Not investment advice. How we work.

Who manages this page This page is managed by aibio.space. The company does not run, edit or pay for this page. News, desk views and Investor Ranks are written and managed independently by aibio.space under our editorial and analytical judgment. Opinion only, not investment advice. How we work · Terms · Request a correction